in vivo News and Research

RSS

Jumping genes help detemine uniqueness of individual brains

Scientists at the Salk Institute for Biological Studies may have found one explanation for the puzzling variety in brain organization and function: mobile elements, pieces of DNA that can jump from one place in the genome to another, randomly changing the genetic information in single brain cells.

15 Jun 2005

Causes, consequences and clinical implications of alcohol-related brain shrinkage

Previous studies have demonstrated that the brains of alcoholics are smaller, lighter and "shrunken" when compared to nonalcoholic brains.

14 Jun 2005

Non-profit public-private partnership develops affordable, new drug regimens for tuberculosis

The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.

14 Jun 2005

Gene therapy for arthritis is both feasible and safe

Gene therapy for arthritis and other non-terminal, debilitating conditions and diseases is both feasible and safe, report researchers who conducted the world's first such test on the approach in patients with advanced rheumatoid arthritis.

6 Jun 2005

HIV/AIDS drugs may also be effective against malaria

Researchers at The Queensland Institute of Medical Research (QIMR) have found that drugs used to treat HIV Aids may also be effective against the biggest killer in the world - malaria.

2 Jun 2005

New Calcitonin drug delivery research holds promise for osteoporosis sufferers

Calcitonin, a hormone that lowers calcium levels in the blood and prevents bone loss, has only been available in an injectable and nasally-administered format to date.

1 Jun 2005

Discovery may lead to therapies to treat the neurological disease

Opening a window to understand the molecular basis of a hereditary ataxia, Dartmouth Medical School researchers have identified an enzyme activity that is inactivated in all reported mutant forms of a disease protein. The discovery may lead to therapies to treat the neurological disease.

29 May 2005

Fluorescence device to diagnose atherosclerosis and tumors

In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.

29 May 2005

Embryonic body wash controls left-right development

Humans and other animals may appear to be symmetrical on the outside, but symmetry is only skin deep. Many body organs, such as the stomach, the heart and the liver, are tipped to the right or left side. So how does the developing embryo distinguish left from right?

20 May 2005

Two-sided coating could breathe life into medical implants

By mimicking an adhesive protein secreted by mussels and a polymer that repels cells and proteins, researchers at Northwestern University have designed a versatile new two-sided coating that could breathe life into medical implants.

15 May 2005

Targeted Genetics announces new patent for Hyperlipidemia

Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."

11 May 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

How Ebola virus infects cells - discovery

Ebola virus reproduction in laboratory-grown cells is severely hampered by enzyme-inhibiting chemicals, and these chemicals deserve further study as possible treatments for Ebola virus infections in humans, report scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID).

23 Apr 2005

New strategy to identify differences between non-metastatic and highly metastatic breast cancer cells

Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.

22 Apr 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Marker for new blood vessel formation in tumors

In a paper in this month's freely-available online global health journal PLoS Medicine, Roland Haubner and colleagues describe how a compound they have developed can be used together with highly sensitive positron emission tomography (PET) scanning to measure the amount of new blood vessel growth in some tumors.

29 Mar 2005

Onconase granted orphan drug status for malignant mesothelioma in Australia

Alfacell Corporation has announced that the Therapeutic Goods Administration (TGA) in Australia has granted Onconase (ranpirnase) Orphan Drug status for the indication of malignant mesothelioma (MM). Onconase is also designated as an Orphan Drug for MM in Europe.

28 Mar 2005

Tiny scaffolding allows stem cells to become working fat cells

Researchers here have used a new microscopic, three-dimensional scaffolding to coax mouse stem cells to transform themselves into fat cells, and then to function identical to how fat cells naturally do in the body.

22 Mar 2005

Smart nanocarrier technology will cancer treatment

A ‘smart’ nanocarrier technology developed by a team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) is set to vastly improve the way cancer patients are treated.

22 Mar 2005

Fundamental mechanisms that may facilitate the design of safer and more efficacious topical drug delivery systems

In a paper published in the Proceedings of the National Academy of Sciences, a group of researchers led by Samir Mitragotri, a professor of chemical engineering at the University of California, Santa Barbara, reports the identification of fundamental mechanisms that may facilitate the design of safer and more efficacious topical drug delivery systems.

16 Mar 2005